OpenURL Connection Search

Select item for more details and to access through your institution.

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Published in:
Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
By:
- Aghajanian, Carol;
- Bell-McGuinn, Katherine M.;
- Burris, Howard A.;
- Siu, Lillian L.;
- Stayner, Lee-Ann;
- Wheler, Jennifer J.;
- Hong, David S.;
- Kurkjian, Carla;
- Pant, Shubham;
- Santiago-Walker, Ademi;
- Gauvin, Jennifer L.;
- Antal, Joyce M.;
- Opalinska, Joanna B.;
- Morris, Shannon R.;
- Infante, Jeffrey R.
Publication type:
Article
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Published in:
Clinical Lung Cancer, 2021, v. 22, n. 5, p. 449, doi. 10.1016/j.cllc.2021.03.010
By:
- Weiss, Jared;
- Goldschmidt, Jerome;
- Andric, Zoran;
- Dragnev, Konstantin H.;
- Gwaltney, Chad;
- Skaltsa, Konstantina;
- Pritchett, Yili;
- Antal, Joyce M.;
- Morris, Shannon R.;
- Daniel, Davey
Publication type:
Article
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
Published in:
Investigational New Drugs, 2012, v. 30, n. 2, p. 662, doi. 10.1007/s10637-010-9604-2
By:
- Bauman, John W.;
- Antal, Joyce M.;
- Adams, Laurel M.;
- Johnson, Brendan M.;
- Murray, Sharon C.;
- Peng, Bin;
- Kirby, Lyndon C.;
- Lebowitz, Peter F.;
- Marbury, Thomas C.;
- Swan, Suzanne;
- Gutierrez, Maria
Publication type:
Article
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Published in:
International Journal of Cancer, 2021, v. 148, n. 10, p. 2557, doi. 10.1002/ijc.33453
By:
- Daniel, Davey;
- Kuchava, Vladimer;
- Bondarenko, Igor;
- Ivashchuk, Oleksandr;
- Reddy, Sreekanth;
- Jaal, Jana;
- Kudaba, Iveta;
- Hart, Lowell;
- Matitashvili, Amiran;
- Pritchett, Yili;
- Morris, Shannon R.;
- Sorrentino, Jessica A.;
- Antal, Joyce M.;
- Goldschmidt, Jerome
Publication type:
Article
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Published in:
Cancer Management & Research, 2021, v. 13, p. 6207, doi. 10.2147/CMAR.S313045
By:
- Hussein, Maen;
- Maglakelidze, Marina;
- Richards, Donald A;
- Sabatini, Marielle;
- Gersten, Todd A;
- Lerro, Keith;
- Sinielnikov, Ivan;
- Spira, Alexander;
- Pritchett, Yili;
- Antal, Joyce M;
- Malik, Rajesh;
- Beck, J Thaddeus
Publication type:
Article
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Published in:
2021
By:
- Hart, Lowell L.;
- Ferrarotto, Renata;
- Andric, Zoran G.;
- Beck, J. Thaddeus;
- Subramanian, Janakiraman;
- Radosavljevic, Davorin Z.;
- Zaric, Bojan;
- Hanna, Wahid T.;
- Aljumaily, Raid;
- Owonikoko, Taofeek K.;
- Verhoeven, Didier;
- Xiao, Jie;
- Morris, Shannon R.;
- Antal, Joyce M.;
- Hussein, Maen A.
Publication type:
journal article
Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP-1 Cells and Murine Microglia.
Published in:
Journal of Neurochemistry, 2000, v. 74, n. 3, p. 1017, doi. 10.1046/j.1471-4159.2000.0741017.x
By:
- Yates, Stephen L.;
- Burgess, Loyd H.;
- Kocsis-Angle, June;
- Antal, Joyce M.;
- Dority, Michael D.;
- Embury, Paula B.;
- Piotrkowski, Anthony M.;
- Brunden, Kurt R.
Publication type:
Article

Found: 7

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP-1 Cells and Murine Microglia.